The goal or the study was to assess if aprotinin, a protease inhibitor, could be used to antagonize in vivo the effects of recombinant tissue-type plasminogen activator (rt-PA). The time coarse of the lysis of a radioactive jugular vein thrombus was monitored continuously with an external gamma counter in anesthetized rabbits. Recombinant (-PA (0.25 mg) was given intravenously as a bolus injection (10% of the dose), followed by a 4 h infusion (90% of the dose). Rabbits received aprotinin 20 min after the start of the infusion as an intravenous bolus Injection at a dose of 60,000 lU/kg (a = 4) or 20,000 lU/kg In = 4).
Recombinant tissue-type plasminogen activator (rt-PA) is a potent thrombolytic drug that is effective in patients with myocardial infarction (1-4). Its use has been associated with major bleeding complication rates of 8% (5), 15% (6) and 17% (2) . Bleeding complications such as cerebral hemorrhage can be life-threatening and with the increasing use of n-PA, their absolute number will increase .
Until recently, no antidote for ri-PA-induced bleeding had been described . It was always thought that in case of hemorrhagic complications . stopping rl-PA administration was sufficient because the half-life of n-PA is short (7) . However, it has been shown that in vivo the rate of thrombolysis is not parallel to the plasma concentration of rt-PA. Thrombolysis can continue without any measurable rt-PA concentration in plasma (8) . This is one reason why the use of a recombinant plasminogen activator inhibitor to antagonize the effects of rt-PA was recently proposed (9) . This specific inhibitor of n-PA reduced the n-PA-induced increase in bleeding time in rabbits . To our knowledge, the clinical use of this inhibitor has not been described, In contrast, aprotinin is a protease inhibitor that has been The rate of lysis in the different groups was compared 2, 60 and 180 min after aprinin administration. Both doses of aprotinin immediately stopped IMomidysis. Thrombdysis was still blocked at 180 ode with the highest dose but not with the lowest dose. Mot , sprtinin could prevent the increasein bleeding time secondary to the iniectkw of rt-PA. These results suggest that apre iia right be 00 in vivo as an antidote for et-PA.
(J Am Coil Cordial`"0Q16:507-ra) 507 used in patients with acute pancreatitis, abnormal blood loss and shock (10). In vitro, aprotinin blocks the thrombolylic effect of plasmin and, in this way, the thrombotytic effects of plasminogen activators (1 I). However. to our knowledge the antagonizing effects of aprotinin on rt-PA-induced thrombolysis have not been tested in vivo .
We recently modified a previously described model (8) to continuously monitor the lysis of ajugular vein thrombus in anesthetized rabbits (8) . In the present study, we assessed the effects of aprotinin during administration of rt-PA in this model. Moreover, because the bleeding time is a relatively good predictor of hemorrhagic events secondary to administration of rt-PA (12). we evaluated the effects of rt-PA on the prolongation of bleeding time .
Methods
Thrombolysis experiments. Burgundy rabbits weighing 2.5 to 3 kg were anesthetized by intravenous injection of pentobarbital (35 mg/kg body weight) (Vetanarcol, Veterinaria AG). Additional pentobarbital was given when needed to maintain anesthesia. The rabbit was tracheotontized and its lungs were ventilated by a mixture of 50% room air and 50% oxygen. A catheter was introduced into a femoral vein for infusing drugs and another catheter was implanted into the femoral artery for blood sampling.
An artificial thrombus was produced in the jugular vein as described by Cotten et al. (12) . Briefly, the external jugular vein was exposed through a paramedial incision in the neck and carefully dissected. Small side branches were ligated and the facial vein was calnulated . A polyester thread (Novolene 4 .0, SSC) was introduced into the jugular vein to maintain the clot in place during lysis. Two clamps were positioned at the proximal and distal parts of the jugular vein segment (approximately 4 cm long), which was then. emptied of all blood by suction through the facial vein catheter. Indium-125-labeled human fibrinogen (Amersham) containing approximately 800,000 counts/min was mixed with the fresh rabbit blood and 10 IU of thrombin (F. Hoffmann-La Roche) and injected into the jupuiar vein segment through the facial vein catheter. The clot was aged for 30 min before both vessel clamps were removed . Then heparin (100 lU/kg) (Liquemin, F. Hoffmann-La Roche) was given intravenously to prevent further incorporation if fibrinogen into the clot . Fifteen minutes after removal of the clamps, administration of rt-FA was started . Wild-type one-chain rt-PA (Genentech) was dissolved in 0.3 M of sodium chloride containing 0 .05% Tween 80 (polysorbate 80) . Aprotinin (Trasylol, Bayer) was dissolved in saline solution. These studies conformed to the Position of the American Heart Association on Research Animal Use . Thrombolysis was evaluated by continuously monitoring the decrease in thrombus radioactivity as a measure of the decrease in thrombus size. For this purpose, a gamma detector (model 8 SHAIMl2, Harsaw) connected to a multichannel analyzer (model ND 62, Nuclear Data) was positioned 2 cm over the jugular vein a few minutes after introduction of the radioactive clot into the isolated jugular vein segment . Radioactivity was continuously recorded with a counting time of 45 s (Fig. 1) was displayed on the multichannel analyzer and recorded on a floppy disk . Stability of the clot was assessed by measuring the radioactivity for 15 min after release of the clamps . At the end of the experiments, residual thrombus was removed and the background radioactivity of the remaining preparation was measured with the detector in the same position as during the thrombolysis experiment .
Protocol . Four groups of rabbits were studied . One group of four rabbits was given only the rt-PA vehicle and was used as the control group. The three other groups received rt-PA (0.25 mg/kg) given as a bolus injection (10% of the total dose) followed by a continuous infusion (v0% of the total dose) over 4 h . Among these three groups, one received only rt-PA (n = 6) and the two others received aprotinin (20,000 IU/kg, n = 4 or 60,000 IU/kg, n = 4) given as a bolus injection 20 min after the start of rt-PA administration . With this design, it was possible to determine whether the thrombus could be lysed during the first 20 min of the study . To assess the effects of aprotinin, we compared the rate of lysis in the different groups 2, 60 and 180 min after administration of aprotinin .
To estimate the rate of lysis, curve fitting was done for each rabbit separately . The counts were adjusted for the initial and the background radioactivity . Only data measured after the time of aprotinin administration (20 min) were used. For rabbits that did not receive aprotinin, a nonlinear regression model (PROC NLIN, SAS Institute) with an exponential decrease was used :
where T is the thrombus size in percent, A is the lysable fraction, L is the theoretically unlysable fraction, t is time and y is the lysis rate . For rabbits that received aprotinin, a cubic polynomial (PROC REG, SAS Institute) was fitted to the data. At 2, 60 and 180 min after administraB9n ofaprotinin, the lysis rate relative to the remaining thrombus at that time was calculated from the estimated regression variables . The effect of the different dosing regimens on the relative lysis rate was compared using a weighted one-way analysis of variance (PROC GLM, SAS Institute) with the factor dose group, Weights were the inverses of the variances of the relative lysis rate in each group.
Bleeding done experiments . Two groups of rabbits were anesthetized and ventilated as in the thrombolysis experiments . Template bleeding time was measured by making a I mm incision in the left ear of the rabbit with a lancet (Autodisc lancet, Boehringer) . The ear of the rabbit was maintained on a surface of water kept at 37°C and the end of bleeding was determined by looking at the blood dropping in water.
Bleeding time was determined at baseline, 5 and I0 min after administration of heparin (100 lU/kg) and 5 min after injection of rt-PA (0 .5 mg/kg followed by 0.5 mg/k& per h). This high dose of rt-PA was chosen because preliminary results showed that lower doses of rt-PA did not increase bleeding time in our experimental model . One group of four rabbits received only rt-PA and the other group of six was treated simultaneously with rt-PA and aprotinin (60,000 IU/kg). Both groups were compared by an unpaired I test .
Results
Thrombolysis experiments . In the control group that did not receive rt-PA, the rate of thrombolysis was very slow (Fig . 1) . In contrast, administration of rt-PA induced rapid thrombolysis with an exponential shape . The bolus injection of aprotinin dramatically slowed thrombolysis in a dosedependent fashion . The rate of lysis in the four experimental groups is given in Table I At 2 min niter administration of aprotinin, the rate of thrombolysis after both doses of aprotinin was equal to the rate of thrombolysis observed in the control group that did not receive rt-PA . At 60 min after injection of aprotinin, the rate of thrombolysis was still decreased with both doses. However, at 180 min after administration of aprotinin, the rate of lysis was decreased only in the high dose group (60,000 IU/kg of aprotinin).
Bleeding time experiments. Bleeding time increased approximately 100% after administration of heparin and by >100% with rt-PA (Fig . 2) . Aprotinin completely prevented this increase in bleeding time . counter. we were able to show that the effect of aprotinin has a very short onset and is long-lasting . Aprotinin is a protease inhibitor that inhibits plasmin. Its clinical indications were recently reviewed (10) . Aprotinin has beep. used in patients with acute pancreatitis, blood loss and shock (10). In vitro, it was shown (11) that aprotinin could block the effects of rt-PA. Our results confirm that aprotinin can also be used in vivo .
The onset of action of aprotinin is very short. This was an interesting point to check because an antidote for rt-PAinduced bleeding could be useful only if it has a very short onset of action; rt-PA has a short half-life (approximately 3 min) in rabbits (7) . Thus, cessation of the infusion of rt-PA leads to a rapid decline in its plasma concentration (7) . However, we recently showed (8) that the time course of the thrombolysis is not parallel to the time course of the plasma concentration of rt-PA . Cessation of the rt-PA infusion leads to a nearly complete arrest of thrombolysis in approximately 1 h (8) . Thus, the advantage of aprotinin is its immediate antagonism of rt-PA.
Another interesting point is that the effect of aprotinin was rather long-lasting, allowing its administration as a bolus dose. However, our results show that the duration of action of aprotinin is clearly dose dependent . A dose of 60,080 IU/kg is needed to obtain a 3 h duration of action .
Effects at sprain on the rt-PA-idaced icrease IN bleeding time. Bleeding time was recently shown (13) to be correlated with bleeding complications during treatment of acute myocardial infarction . Thus, it was important to show that aprotinin not only could stop the throenbolytic effect of rt-PA, but also prevent the increase of bleeding time due to n-PA . Recently, recombinant plasminogen activator inhibitor I was shown (9) 
